Esophagogastric Cancer Patients with High DKK1 Levels Respond Better to DKN-01, Keytruda Combo, Phase 1 Trial Shows
News
A combination of Leap Therapeutics‘ investigational therapy DKN-01 plus Keytruda (pembrolizumab) led to “highly encouraging” responses and survival outcomes in a population of advanced esophagogastric cancer patients with elevated levels of ... Read more